Primary tumor location and survival in colorectal cancer: A retrospective cohort study
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Trifluridine/tipiracil plus bevacizumab prolongs survival in refractory colorectal cancer
Overall survival for colorectal cancer patients treated with FOLFIRI®... | Download Scientific Diagram
A) Curve for progression-free survival in patients with metastatic... | Download Scientific Diagram
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis | Aging
New Treatment Options for Colorectal Cancer
PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Frontiers | FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 | British Journal of
Frontiers | Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial -
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis | Scientific Reports
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry | BMC Gastroenterology | Full Text
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer | British Journal of Cancer
A) Progression-free survival (PFS) and (B) overall survival (OS) for... | Download Scientific Diagram
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). | Semantic Scholar
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer - ScienceDirect
Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis | PLOS ONE